Levetiracetam-induced myoclonic status epilepticus in myoclonic-astatic epilepsy: A case report

Epileptic Disorders

Volumn 8, Issue 3, 2006, Pages 213-218

  Kröll Seger, Judith ^a   Mothersill, Ian William ^a   Novak, Simon ^a   Sälke Kellermann, Ritva Anneli ^a   Krämer, Günter ^a  

^a SWISS EPILEPSY CENTER   (Switzerland)

Author keywords

Aggravating effect of AEDs; Doose's syndrome; Levetiracetam; Myoclonic status epilepticus; Myoclonic astatic epilepsy

Indexed keywords

ETHOSUXIMIDE; ETIRACETAM; MIDAZOLAM; VALPROIC ACID;

ARTICLE; ATONIC SEIZURE; BRAIN REGION; CASE REPORT; CLINICAL FEATURE; ELECTROENCEPHALOGRAPHY; ELECTROMYOGRAPHY; EPILEPTIC STATE; FAMILY HISTORY; HUMAN; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL;

ANTICONVULSANTS; BEHAVIOR; CHILD, PRESCHOOL; ELECTROENCEPHALOGRAPHY; ELECTROMYOGRAPHY; EPILEPSIES, MYOCLONIC; ETHOSUXIMIDE; HUMANS; MALE; PIRACETAM; STATUS EPILEPTICUS;

EID: 33749595624     PISSN: 12949361     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Atefy R, Tettenborn B. Nonconvulsive status epilepticus on treatment with levetiracetam. Epilepsy Behav 2005; 6: 613-6.
2. Bauer J. Seizure-inducing effects of antiepileptic drugs: a review. Acta Neurol Scand 1996; 94: 367-77.
3. Bird JM, Joseph ZA. Levetiracetam in clinical use- a prospective observational study. Seizure 2003; 12: 613-6.
4. Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for classification of epilepsies and epileptic syndromes. Epilepsia 1989; 30: 389-99.
5. Coppola G, Mangano S, Tortorella G, et al. Levetiracetam during 1-year follow-up in children, adolescents, and young adults with refractory epilpesy. Epilepsy Res 2004; 59: 35-42.
6. De los Reyes EC, Sharp GB, Hale SE. Levetiracetam in the treatment of Lennox-Gastaut syndrome. Ann Neurol 2004; 50 (Suppl 1): S108.
7. Di Bonaventura C, Fattouch J, Mari F, et al. Clinical experience with levetiracetam in idiopathic generalized epilepsy according to different syndrome subtypes. Epileptic Disord 2005; 7(3): 231-5.
8. Doose H. Myoclonic astatic epilepsy of early childhood. In: Roger J, Dravet C, Bureau M, Dreifus FE, Perret A, Wolf P, eds. Epileptic syndromes in infancy, childhood and adolescence. London: John Libbey, 1992: 103-14.
9. Doose H, Gerken H, Leonhardt R, et al. Centrencephalic myoclonic astatic petit mal. Clinical and genetic investigation. Neuropediatrics 1970; 2: 59-78.
10. Dulac O, Plouin P, Shewmon A. Myoclonus and epilepsy in childhood: 1996 Royaumont meeting. Epilepsy Res 1998; 30: 91-106.
11. Gelisse P, Crespel A, Genton P, et al. Dramatic effect of levetiracetam on epileptic negative myoclonus. Acta Neurol Scand 2003; 107: 302-3.
12. Genton P, Gelisse P. Antimyoclonic effect of levetiracetam. Epileptic Disord 2000; 2: 209-12.
13. Glauser TA, Dulac O. Preliminary efficacy of levetiracetam in children. Epileptic Disord 2003; 5: S45-S50.
14. Grosso S, Franzoni E, Coppola G, et al. Efficacy and safety of levetiracetam: an add-on trial in children with refractory epilepsy. Seizure 2005; 14: 248-53.
15. Guerrini R, Belmonte A, Genton P. Antiepileptic drug-induced worsening of seizures in children. Epilepsia 1998; 39(Suppl 3): S2-S10.
16. Guerrini R, Bonanni P, Rothwell J, et al. Myoclonus and epilepsy. In: Guerrini R, Aicardi J, Andermann F, Hallett M, eds. Epilepsy and movement disorder. Cambridge: Cambridge University press, 2002: 165-210.
17. Guerrini R, Parmeggiani L, Bonanni P, et al. Epileptic syndromes in infancy, childhood and adolescence. London: John Libbey, 2005; (115-24).
18. Kaminska A, Ickowicz A, Plouin P, et al. Delineation of cryptogenic Lennox-Gastaut syndrome and myoclonic astatic epilepsy using multiple correspondence analysis. Epilepsy Res 1999; 36: 15-29.
19. Lagae L, Buyse G, Deconinck A, et al. Effect of levetiracetam in refractory childhood epilepsy syndromes. Eur J Paediatr Neurol 2003; 7: 123-8.
20. Lortie A, Chiron C, Mumford J, et al. The potential for increasing seizure frequency, relapse, and appearance of new seizure types with vigabatrin. Neurology 1993; 43(Suppl 5): S24-S27.
21. Nakken KO, Eriksson AS, Lossius R, et al. A paradoxical effect of levetiracetam may be seen in both children and adults. Seizure 2003; 12: 42-6.
22. Oguni H, Tanaka T, Hayashi K, et al. Treatment and long-term prognosis of myoclonic-astatic epilepsy of early childhood. Neuropediatrics 2002; 33: 122-32.
23. Perucca E, Johannessen SI. The ideal pharmakokinetic properties of an antiepileptic drug: how close does levetiracetam come. Epileptic Disord 2003; 5(Suppl. 1): S17-S26.
24. Sander JW, Mitchell TN. Levetiracetam: a new antiepileptic drug for the adjunctive therapy of chronic epilepsy. Drugs Today 2001; 37: 665-73.
25. Tan MJ, Appleton RE. Efficacy and tolerability of levetiracetam in children aged 10 years and younger: a clinical experience. Seizure 2004; 13: 142-5.
26. Wheless JW, Ng YT. Levetiracetam in refractory pediatric epilepsy. J Child Neurol 2002; 17: 413-5.